{"id":37714,"date":"2017-01-09T08:10:36","date_gmt":"2017-01-09T13:10:36","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37714"},"modified":"2017-01-09T08:10:36","modified_gmt":"2017-01-09T13:10:36","slug":"cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714","title":{"rendered":"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Cempra Inc (NASDAQ:CEMP)<\/strong> kicked into the New Year with a bang, by making announcement of its Phase 3 clinical trials of solithromycin by Toyama Chemical Co., Ltd.\u00a0 The FUJIFILM Holdings Corporation\u2019s subsidiary, Toyama has exclusive R&amp;D rights of Cempra\u2019s solithromycin in Japan. Solithromycin is said to be Cempra\u2019s lead product, which is licensed in Japan to the strategic commercial partner.<\/p>\n<h2 style=\"text-align: justify;\"><strong>Why to focus on Japan?<\/strong><\/h2>\n<p style=\"text-align: justify;\">Japan to antibiotic industry is one of the most important markets. Imagine not leveraging on the 2<sup>nd<\/sup> largest antibiotic market across the globe! By targeting Japan, Cempra will have an Asian base, which is not just great for the company, but also allows it to build a credible repute.<\/p>\n<p style=\"text-align: justify;\">Among Cempra\u2019s lead products, Solithromycin plays a vital role. This is an approved treatment for community-acquired bacterial pneumonia (CABP) among other respiratory infections. Toyama, which is the company\u2019s strategic commercial partner, completed the Phase 2 multi-center double-blinded study of treatment in Japan. This included 135 patients. The trial fetched it positive results, thus preceding the treatment drug to Phase III.<\/p>\n<p style=\"text-align: justify;\">Japan\u2019s Pharmaceuticals and Medical Devices Agency\u00a0(PMDA) have already given the nod to initiate Phase III after valid review. Cempra receives milestone payments every time Toyama announces something like this. During Phase III announcement, Cempra in the U.S. became eligible for $10 million\u00a0milestone payment, which fetched it great applause from the investors too.<\/p>\n<p style=\"text-align: justify;\">Cempra, as of now, has received a total amount of $70 million through this product in Japan. Given the importance of this product and also the country, Japan will indeed be important for Cempra.<\/p>\n<p style=\"text-align: justify;\">Not only will it allow the company to have a solid Asian presence, but will also fetch it great revenues in the home. With a positive and profitable start to the New Year, Cempra has definitely started off the race with a lead. Will it be able to run off with distinction? We\u2019ll let future decide this, while Cempra enjoys the initial weeks of New Year on a resourceful note.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cempra Inc (NASDAQ:CEMP) kicked into the New Year with a bang, by making announcement of its Phase 3 clinical trials of solithromycin by Toyama Chemical [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":37715,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12188,12186,12189,12187,12191,12190],"stock_ticker":[],"class_list":["post-37714","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-cempra-inc","tag-cempra-inc-nasdaqcemp","tag-japanese-market","tag-nasdaqcemp","tag-solithromycin","tag-solithromycin-phase-3-clinical-trials","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Cempra Inc (NASDAQ:CEMP) kicked into the New Year with a bang, by making announcement of its Phase 3 clinical trials of solithromycin by Toyama Chemical [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-09T13:10:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials\",\"datePublished\":\"2017-01-09T13:10:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714\"},\"wordCount\":351,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg\",\"keywords\":[\"Cempra Inc\",\"Cempra Inc (NASDAQ:CEMP)\",\"Japanese market\",\"NASDAQ:CEMP\",\"Solithromycin\",\"Solithromycin Phase 3 Clinical Trials\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714\",\"name\":\"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg\",\"datePublished\":\"2017-01-09T13:10:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg\",\"width\":400,\"height\":400,\"caption\":\"Cempra Inc\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714","og_locale":"en_US","og_type":"article","og_title":"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials - Wall Street PR","og_description":"Cempra Inc (NASDAQ:CEMP) kicked into the New Year with a bang, by making announcement of its Phase 3 clinical trials of solithromycin by Toyama Chemical [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-01-09T13:10:36+00:00","og_image":[{"width":400,"height":400,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials","datePublished":"2017-01-09T13:10:36+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714"},"wordCount":351,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg","keywords":["Cempra Inc","Cempra Inc (NASDAQ:CEMP)","Japanese market","NASDAQ:CEMP","Solithromycin","Solithromycin Phase 3 Clinical Trials"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714","url":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714","name":"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg","datePublished":"2017-01-09T13:10:36+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/01\/Cempra-Inc.jpg","width":400,"height":400,"caption":"Cempra Inc"},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cempra-inc-nasdaqcemp-to-target-japanese-market-with-solithromycin-phase-3-clinical-trials-37714#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Cempra Inc (NASDAQ:CEMP) To Target Japanese Market With Solithromycin Phase 3 Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37714"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37714\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/37715"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37714"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}